About MannKind Corporation
https://www.mannkindcorp.comMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes.
CEO
Michael E. Castagna
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-03-03 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 137
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:28.71M
Value:$161.06M
BLACKROCK INC.
Shares:22.56M
Value:$126.55M
VANGUARD GROUP INC
Shares:17.63M
Value:$98.91M
Summary
Showing Top 3 of 272
About MannKind Corporation
https://www.mannkindcorp.comMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $82.13M ▲ | $43.15M ▼ | $7.99M ▲ | 9.72% ▲ | $0.03 ▲ | $17.87M ▲ |
| Q2-2025 | $76.53M ▼ | $50.66M ▲ | $668K ▼ | 0.87% ▼ | $0 ▼ | $9.75M ▼ |
| Q1-2025 | $78.35M ▲ | $38.55M ▲ | $13.16M ▲ | 16.79% ▲ | $0.04 ▲ | $26.9M ▲ |
| Q4-2024 | $76.78M ▲ | $30.68M ▼ | $7.42M ▼ | 9.67% ▼ | $0.03 ▼ | $18.61M ▼ |
| Q3-2024 | $70.08M | $39.3M | $11.55M | 16.48% | $0.04 | $23.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $260.04M ▲ | $494.64M ▲ | $539.19M ▲ | $-44.55M ▲ |
| Q2-2025 | $178.99M ▼ | $411.7M ▲ | $466.74M ▼ | $-55.04M ▲ |
| Q1-2025 | $181.54M ▼ | $410.14M ▲ | $468.76M ▼ | $-58.62M ▲ |
| Q4-2024 | $197.26M ▼ | $393.84M ▼ | $472.66M ▼ | $-78.82M ▲ |
| Q3-2024 | $251.59M | $464.2M | $674.13M | $-209.93M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $7.99M ▲ | $23.49M ▲ | $-25.06M ▼ | $71.96M ▲ | $70.39M ▲ | $22.36M ▲ |
| Q2-2025 | $668K ▼ | $8.95M ▲ | $6.26M ▲ | $-5.51M ▼ | $9.7M ▲ | $7.83M ▲ |
| Q1-2025 | $13.16M ▲ | $-6.38M ▼ | $5.96M ▼ | $1.39M ▲ | $975K ▲ | $-6.71M ▼ |
| Q4-2024 | $7.42M ▼ | $22.64M ▲ | $48.22M ▲ | $-86.9M ▼ | $-16.03M ▲ | $19.75M ▲ |
| Q3-2024 | $11.55M | $9.33M | $-41.26M | $-2.34M | $-34.27M | $7.91M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 License And Service | $0 ▲ | $0 ▲ | $0 ▲ | $30.00M ▲ |
 Product | $60.00M ▲ | $0 ▼ | $0 ▲ | $20.00M ▲ |
 Product Revenue | $0 ▲ | $50.00M ▲ | $40.00M ▼ | $0 ▼ |
 Royalty | $80.00M ▲ | $30.00M ▼ | $30.00M ▲ | $30.00M ▲ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Michael E. Castagna
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-03-03 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 137
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:28.71M
Value:$161.06M
BLACKROCK INC.
Shares:22.56M
Value:$126.55M
VANGUARD GROUP INC
Shares:17.63M
Value:$98.91M
Summary
Showing Top 3 of 272